Ongoing Clinical Trials in BRAF-Mutant CRC

January 15, 2018
Cathy Eng, MD, FACP

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in the <em>BRAF</em>-mutant colorectal cancer patient population.

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in theBRAF-mutant colorectal cancer patient population.

The most recent study presented for theBRAF-mutant population was SWOG S1406, which looked at a control arm of irinotecan and cetuximab with or without vemurafenib inBRAF-mutant metastatic colorectal cancer. The study was positive for progression-free survival, which was the primary endpoint.

Eng believes this was an eye-opening study in that it suggests testing patients for the presence of aBRAFmutation and providing patients with a BRAF inhibitor.